Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MWN109 in Non-Diabetic Participants With Overweight or Obesity
NCT07791654Phase 2
Key facts
- Status
- Completed
- Start
- Aug 2025
- Primary completion
- Mar 2026
- Countries
- 1
- Drugs
- MWN109
- Conditions
- Overweightobesity
01
Overview
Phase 2, randomised, double-blind trial of MWN109 in Overweight and obesity (4 arms), sponsored by Shanghai Minwei Biotechnology Co., Ltd. Primary endpoint: Percentage change in body weight compared to baseline at 24 weeks. Started Aug 2025; status: completed.
02
Design
4 arms- Study design
- RandomizedDouble-blind
MWN109 Cohort 1
MWN109 1 administered SC, QW, 24 weeks
MWN109 Cohort 2
MWN109 2 administered SC, QW, 24 weeks
MWN109 Cohort 3
MWN109 3 administered SC, QW, 24 weeks
Placebo
Placebo administered SC, QW, 24 weeks
03
Who it enrols
Adults aged 18-65 with BMI >= 30 (or >= 27 with weight-related comorbidity), non-diabetic, with a history of weight control efforts. Excludes patients with diabetes, pancreatitis, medullary thyroid carcinoma, recent cardiovascular events, or severe depression.
04
Endpoints
Primary
Percentage change in body weight compared to baseline
Secondary
Change in body weight from baseline over time
Proportion of Participants Achieving >=5% Body Weight Reduction from Baseline
Proportion of Participants Achieving >=10% Body Weight Reduction from Baseline
Proportion of Participants Achieving >=15% Body Weight Reduction from Baseline
Proportion of Participants Achieving >=20% Body Weight Reduction from Baseline
Change from baseline in waist circumference over time
Change from baseline in body mass index (BMI) over time
Change from baseline in lipid profile over time
Beyond the preview
Go deeper on NCT07791654.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07791654.